Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasm Metastasis 4Neoplasms 3Breast Neoplasms 3Colorectal Neoplasms 2Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Prostatic Diseases 1Male Urogenital Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Genital Diseases, Male 1Endometrial Neoplasms 1Colonic Neoplasms 1Breast Neoplasm Malignant Female 1Advanced Cancer 1

Interventions

pembrolizumab 4Pemetrexed 3Paclitaxel 3Fulvestrant 2FANG vaccine 2Drug Therapy 2Carboplatin 2tucatinib 1trastuzumab deruxtecan 1seribantumab 1selinexor 1osimertinib 1gedatolisib 1dactolisib 1cobimetinib 1cemiplimab 1atezolizumab 1Watchful Waiting 1Trastuzumab 1Transurethral Resection of Prostate 1Trabectedin 1Therapeutics 1Sutures 1Radiation 1Quality of Life 1Pregnancy Tests 1Patient Reported Outcome Measures 1Oxaliplatin 1OSI 930 1Molecular Diagnostic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Uterine Neoplasms × gedatolisib × Clear all
NCT01420081 2019-01-08

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Pfizer

Phase 2 Terminated
67 enrolled 37 charts
Gynecologic

Neoplasm Metastasis, Neoplasms, Recurrence, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡